Pathologic stage I non–small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: Clinicopathologic characteristics and prognosis

Matsuguma, Haruhisa; Nakahara, Rie; Igarashi, Seiji; Ishikawa, Yoshinori; Suzuki, Haruko; Miyazawa, Naoto; Honjo, Satoshi; Yokoi, Kohei

doi:10.1016/j.jtcvs.2007.09.032

Cited by 61 publications

(52 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we evaluated the clinical significance of the serum CEA level in patients with clinical stage IA NSCLC. Several studies have reported that the preoperative CEA level is an independent prognostic factor in patients surgically treated for clinical stage I NSCLC (16,17). However, the preoperative CEA level was not determined to be an independent prognostic factor in patients with clinical stage I NSCLC by multivariate analysis in the present study.…”

Section: Discussioncontrasting

confidence: 70%

Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Background: The objective of this study was to assess the preoperative serum carcinoembryonic antigen (CEA) level in patients with clinical stage IA non-small cell lung cancer (NSCLC) and to evaluate its clinical significance.Methods: Between January 2005 and December 2014, a total of 378 patients with clinical stage IA NSCLC underwent complete resection with systematic node dissection. The survival rate was estimated starting from the date of surgery to the date of either death or the last follow-up by the Kaplan-Meier method. Univariate analyses by log-rank tests were used to determine prognostic factors. Cox proportional hazards ratios were used to identify independent predictors of poor prognosis. Clinicopathological predictors of lymph node metastases were evaluated by logistic regression analyses. Results:The 5-year survival rate of patients with an elevated preoperative serum CEA level was significantly lower than that of patients with a normal CEA level (75.5% vs. 87.7%; P=0.02). However, multivariate analysis did not show the preoperative serum CEA level to be an independent predictor of poor prognosis. Postoperative pathological factors, including lymphatic permeation, visceral pleural invasion, and lymph node metastases, tended to be positive in patients with an elevated preoperative serum CEA level. In addition, the CEA level was a statistically significant independent clinical predictor of lymph node metastases. Conclusions: The preoperative serum CEA level was not an independent predictor of poor prognosis in patients with pathological stage IA NSCLC but was an important clinical predictor of tumor invasiveness and lymph node metastases in patients with clinical stage IA NSCLC. Therefore, measurement of the preoperative serum CEA level should be considered even for patients with early-stage NSCLC.

show abstract

Section: Discussioncontrasting

confidence: 70%

Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Among these, the degree of local tumor invasion has been considered to play an important role in the increase of serum CEA levels (Zamcheck et al, 1975, Hamada et al, 1985. In NSCLC, it had been reported that high serum CEA levels showed significantly higher rates of pleural invasion and vascular invasion in p-stage I disease (Matsuguma et al, 2008). Therefore it is considered that serum CEA levels in lung adenocarcinoma increase as local tumor invasion progresses.…”

Section: Discussionmentioning

confidence: 99%

Correlation between Serum Carcinoembryonic Antigen Level and Histologic Subtype in Resected Lung Adenocarcinoma

Tomita

Ayabe²,

Chosa³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…In addition, blood-based biomarkers have a great advantage of being evaluated easily and repeatedly. Among blood-based biomarkers, serum CEA is most extensively examined, and several studies showed that serum CEA was a useful marker not only to discriminate lung cancer, especially adenocarcinoma of the lung, from benign diseases but also to determine tumor progression and prognosis (13,14). Despite these promising results, routine use of serum CEA in clinical practice is not recommended mainly due to its insufficient sensitivity and/or specificity as well as lack of reproducibility of the results (16,17).…”

Section: Discussionmentioning

confidence: 99%

“…following a manufacturer's instruction; the manufacturer-suggested cutoff point of CEA to discriminate between nonmalignant disease and malignant tumor was 5 ng/mL (13,14). For patients with a suspicion of primary lung cancer, bronchoscopic and/or trans-thoracic needle biopsy was applied to obtain pathologic diagnosis; if failed, video-assisted thoracoscopic biopsy was done.…”

Section: Methodsmentioning

confidence: 99%

Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer

Tanaka

Yoneda

Kondo

et al. 2009

Clinical Cancer Research

281

241

View full text Add to dashboard Cite

Purpose: To investigate the diagnostic performance of circulating tumor cells (CTC) in discrimination between primary lung cancer and nonmalignant diseases as well as in prediction of distant metastasis. Patients and Methods: We prospectively evaluated CTCs in 7.5-mL samples of peripheral blood sampled from patients with a suspicion or a diagnosis of primary lung cancer. A semiautomated system was used to capture CTCs with an antibody against epithelial cell adhesion molecule. Results: Of 150 eligible patients, 25 were finally diagnosed as having nonmalignant disease, and 125 were diagnosed as having primary lung cancer with (n = 31) or without (n = 94) distant metastasis. CTCs were detected in 30.6% of lung cancer patients and in 12.0% of nonmalignant patients. CTC count was significantly higher in lung cancer patients than in nonmalignant patients, but a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between lung cancer and nonmalignant diseases with an area under ROC curve of 0.598 (95% confidence interval, 0.488-0.708; P = 0.122). Among lung cancer patients, CTC count significantly increased along with tumor progression, especially with development of distant metastasis. The area under ROC curve for CTC count in prediction of distant metastasis was 0.783 (95% confidence interval, 0.679-0.886; P < 0.001). When patients with one or more CTCs were judged as having metastatic disease, sensitivity and specificity of the CTC test were 71.0% and 83.0%, respectively. Conclusions: CTC is a useful surrogate marker of distant metastasis in primary lung cancer. (Clin Cancer Res 2009;15(22):6980-6)

show abstract

Pathologic stage I non–small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: Clinicopathologic characteristics and prognosis

Abstract: Patients with resected pathologic stage I non-small cell lung cancer and high preoperative serum carcinoembryonic antigen levels are a subgroup with a distinctly poor prognosis who display smoking-related clinicopathologic characteristics.

Cited by 61 publications

References 16 publications

Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer

Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer

Correlation between Serum Carcinoembryonic Antigen Level and Histologic Subtype in Resected Lung Adenocarcinoma

Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer

Contact Info

Product

Resources

About